Premium
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning
Author(s) -
Lasica Masa,
Taylor Emma,
Bhattacharyya Puja,
Bennett Ashwini,
Cooke Rachel E.,
Stern Catharyn,
Agresta Franca,
Ayton Rosemary,
Grigg Andrew
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12737
Subject(s) - medicine , melphalan , carmustine , fertility , incidence (geometry) , etoposide , gynecology , chemotherapy , surgery , population , physics , environmental health , optics
There is currently minimal data on fertility outcomes in premenopausal women undergoing autologous stem cell transplant ( ASCT ) with carmustine, etoposide, cytarabine and melphalan ( BEAM ) conditioning. A retrospective analysis of fertility outcomes in premenopausal females aged between 18 and 40 yr who underwent BEAM / ASCT for lymphoma between 1995 and 2011 was performed at four transplant centres. Of 41 premenopausal women who underwent BEAM conditioning, 25 met the inclusion criteria with the main exclusion criterion being inadequate documentation. Eighteen had Hodgkin lymphoma, and seven had non‐Hodgkin lymphoma. Median number of chemotherapy regimens pretransplant was 2 (1–3). Seventeen women (68%) with a median age at transplant of 25 yr (range 17–33) recovered their menses. The comparative group without recovery was older with a median age of 34 yr (range 20–40) ( P = 0.007). Ten patients, with a median age at transplant of 22 yr (range 17–30), had 15 naturally conceived pregnancies. Chemotherapy regimens and lymphoma type did not obviously influence the incidence of menses recovery or conception. The incidence of recovery of menses and fertility in premenopausal women undergoing BEAM / ASCT for lymphoma is substantial. Younger age at transplant correlates with superior fertility outcomes.